VolitionRx (NYSE:VNRX) Rating Reiterated by Cantor Fitzgerald

VolitionRx (NYSE:VNRX)‘s stock had its “overweight” rating reaffirmed by Cantor Fitzgerald in a note issued to investors on Wednesday, Benzinga reports. They presently have a $2.50 price target on the stock. Cantor Fitzgerald’s price target would indicate a potential upside of 226.75% from the stock’s current price.

VolitionRx Stock Performance

Shares of VNRX opened at $0.77 on Wednesday. The company has a current ratio of 0.69, a quick ratio of 0.69 and a debt-to-equity ratio of 0.56. The firm has a market cap of $62.79 million, a PE ratio of -1.50 and a beta of 1.38. The company’s 50 day simple moving average is $0.99 and its 200-day simple moving average is $0.87. VolitionRx has a 12-month low of $0.55 and a 12-month high of $2.10.

VolitionRx (NYSE:VNRX) last announced its earnings results on Monday, March 25th. The company reported ($0.11) earnings per share (EPS) for the quarter. The business had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.50 million. VolitionRx had a negative return on equity of 7,185.73% and a negative net margin of 4,557.29%. As a group, equities analysts predict that VolitionRx will post -0.39 EPS for the current year.

Institutional Investors Weigh In On VolitionRx

A hedge fund recently bought a new stake in VolitionRx stock. Silverberg Bernstein Capital Management LLC bought a new stake in VolitionRx Limited (NYSE:VNRX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned 0.19% of VolitionRx as of its most recent filing with the Securities & Exchange Commission. 8.09% of the stock is owned by institutional investors and hedge funds.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes.